Targeted cell lines Clonexpress offers patient-specific differentiated cell types including pancreatic beta cells, hepatocytes, dopaminergic neurons, and CNS cell lines suitable for licensing or purchase, presenting opportunities to position these as high-fidelity models for drug discovery, safety/toxicity screening, and disease modeling.

Custom cell development The company specializes in custom development of tumor-derived cell lines and primary-cell based lines from client samples, enabling this capability as a service for personalized oncology studies, biomarker discovery, and translational research collaborations.

Cancer mechanism platform Clonexpress has identified a growth-control mechanism present in cancers but not in normal fibroblasts, with a sensitive assay for target identification, offering a potential co-development or licensing path for novel anticancer therapies and companion diagnostics.

Research-grade CNS portfolio A broad CNS cell portfolio including neuronal progenitors, dopaminergic neurons, astrocytes, and microglia provides opportunities for neuroscience drug screening, neurodegenerative disease modeling, and toxicity assessments in partner labs or CRO engagements.

Funding and collaborations With revenue in the low to mid single digits and active partnership interests, there is a clear channel for strategic collaborations, multi-project licenses, and paid R&D services to scale development of their proprietary cell lines and cancer-targeting platform.